| Cat.No. | Name | Information |
|---|---|---|
| M1743 | X-376 | X-376 is a potent and highly specific ALK small molecule tyrosine kinase inhibitor with IC50 of 0.61 nM. |
| M1873 | LDN-193189 | LDN-193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3. |
| M1720 | AP26113 (Brigatinib) | AP26113 (Brigatinib) is a highly potent ALK inhibitor with IC50 of 0.6 nM. |
| M2075 | LDK378 | Ceritinib (LDK378) is a highly selective, orally bioavailable ALK inhibitor with IC50 of 0.15 nM. |
| M1794 | SB431542 | SB-431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM). |
| M1950 | ASP3026 | ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. |
| M45164 | APG-2449 | APG-2449 is an orally active, potent ALK/ROS1/FAK inhibitor with anti-tumor activity in a mouse model of non-small cell lung cancer (NSCLC). |
| M43471 | ALK2-IN-5 | ALK2-IN-5, pyrazolopyrimidine compound, is an ALK2 inhibitor. |
| M43470 | J-1048 | J-1048 is an activin receptor-like kinase 5 (ALK5) inhibitor. |
| M43469 | CPD-1224 | CPD-1224 is an orally active derivative of ALK inhibitors to cereblon ligands. |
| M43468 | Ack1 inhibitor 1 | Ack1 inhibitor 1 is a potent, selective, and orally active inhibitor of ACK1 kinase with an IC50 value of 2.1 nM. |
| M29632 | M4K2234 | M4K2234 (compound 26b) is an ALK2 inhibitor. M4K2234 inhibits ALK2 and ALK5 with IC50s of 5 and 2144 nM, respectively. M4K2234 can be used as a chemical probe for ALK1 and ALK2 protein kinases. M4K2234 can be used for the research of cancer. |
| M29396 | Ficonalkib | Ficonalkib is a potent inhibitor of Anaplastic lymphoma kinase (ALK), the tyrosine kinase receptor. Ficonalkib, can be used as an antineoplastic agent. |
| M28969 | Envonalkib citrate | Envonalkib citrate is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib citrate can be used for the research of non-small cell lung cancer. |
| M28954 | Iruplinalkib | Iruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of ALK and ROS1 tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement. |
| M28756 | JH-VIII-157-02 | JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC50 of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells. |
| M28499 | ALK kinase inhibitor-1 | ALK kinase inhibitor-1 is an anaplastic lymphoma kinase (ALK) inhibitor. |
| M24696 | Ascrinvacumab | Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC). |
| M21110 | Con B-1 | ConB-1 is a strongly selective ALK inhibitor with low toxicity to normal cells. |
| M20040 | WAY-270947 | WAY-270947 is a ALK5 inhibitor. |
| M14147 | TPX-0131 | The CNS-penetrant ALK kinase inhibitor TPX-0131 was more potent in vitro against WT-ALK and many ALK resistance mutations than all five approved ALK inhibitors. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
